Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema

In May 2020 and February 2021, capmatinib and tepotinib, respectively were approved by the Food and Drug Administration (FDA) for the treatment of metastatic non‐small cell lung carcinoma harboring mesenchymal‐epithelial transition (MET) exon 14 skipping alterations. Herein, we present a case of int...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunimasa, Kei, Kawamura, Takahisa, Tamiya, Motohiro, Inoue, Takako, Kuhara, Hanako, Nishino, Kazumi, Kumagai, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671889/
https://www.ncbi.nlm.nih.gov/pubmed/34695875
http://dx.doi.org/10.1111/1759-7714.14205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671889/
https://www.ncbi.nlm.nih.gov/pubmed/34695875
http://dx.doi.org/10.1111/1759-7714.14205

Ejemplares similares